Dried blood spots (DBS) are frequently used in clinical testing for biosurveillance, infectious 31 disease and confirmatory testing, and clinical trials, particularly for populations in remote areas.
Background 49
The ability to easily and efficiently collect, preserve, and transport high quality biospecimens is 50 critical for the success of clinical screening and biosurveillance programs for infectious pathogen 51 detection, particularly among populations living in remote and/or low resourced areas. Dried 52 blood spots (DBS) offer a simple and practical alternative to acquire specimens in cases where 53 traditional blood collection methods involving venipuncture by a trained phlebotomist or on site 54 centrifugation of fresh blood samples may not be feasible [1] [2] [3] [4] 
Ethical considerations 150
The results reported represent an analysis of a quality assurance activity on clinical discard 151 samples or commercial panel materials within an existing clinical regulated activity. The 152 WRAIR Human Subjects Protection Branch has determined this study (WRAIR #2188) involves 153 analysis of anonymized samples with no link to individual patients. As such, the study does not 154 meet the definition of research involving Human Subject, and no IRB Review was required. 155 156
Results 157
The recovery of HIV Ag/Ab Combo EIA signal from HS and 903 DBS was evaluated on serial 158 dilutions of an HIV reactive clinical sample diluted in normal human blood up to a 1:10,000 159 dilution (Fig. 2) . Values for signal to cut-off (S/CO) greater than 1.0 are considered reactive. 160 on July 25, 2018 by guest http://jcm.asm.org/
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The original plasma sample yielded the highest S/CO signal; and was reactive at up to a 1:1,000 161 dilution while the HS and 903 samples were reactive at a 1:100 dilution. descending order of HS S/CO, with the last two members being the negative panel members (Fig  179  4) . Again, the original plasma samples gave the highest signals. The S/CO signal of the low 180 titer samples showed consistently better recovery than those from the 903 card, except for 181 member #12. Two HS and three 903 samples prepared from the very low plasma reactive 182 members of PRA204 were non-reactive (Fig. 4) . The two negative PRA204 samples were also 183 negative on both HS and 903. 184
Based on the results of the 51 clinical and 18 PRA204 panel members, we calculated the 185 sensitivity of the 903 at 93.5%, and of HS at 95.6%, with a Specificity and Positive Predictive 186
Value of 100% for both ( Table 2 ). The Negative Predictive value was 88.5% for 903 and 92.0% 187 HS, with accuracy at 95.7% and 97.1%, respectively. 188
The recovery of low titer HIV-1 antibody signal from early infection was also evaluated by the 189 third Generation HIV-1/2/O EIA on both 903 and HS using the SeraCare PRB914 and PRB947 190 seroconversion panels (Fig. 5) . The signal from the HS DBS was consistently higher than from 191 903, with all positive members being detected except for one member (PRB914-03) that was just 192 below the cut-off value for the 903 sample. The first member of PRB947 was HIV 1/2/O non-193 reactive on the original plasma and was also non-reactive on both the HS and 903. reactive members from SeraCare HIV-1 seroconversion panels (Fig 8) . desiccant extended stability, suggesting that humidity rather than temperature alone is the 287 significant factor in loss of reactivity. The HS sample showed superior recovery and stability to 288 903 cards under these conditions if protected from high humidity and temperature in a Ziploc 289 bag with additional desiccant. 290
Our studies had several limitations. The use of simulated samples prepared from frozen plasma 291 or serum diluted in whole blood may not perform identically to those collected in the field.
292
Dilutions of sample in whole blood as used in Fig 2, is not equivalent to low reactive samples 293 present in early infection. The volumes of serum used in the laboratory testing (75lfor HIV-294 1/2/O and HIV Ag/Ab Combo, 5lfor Geenius) are higher than the equivalent volume 295 recovered from HS and 903, which can account at least in part for the lower sensitivity of DBS. 296
We have shown that samples collected as DBS including Whatman 903 cards and HemaSpot 297 provide reliable test results in HIV screening (HIV 1/2/O, HIV-1/2 Ag/Ab Combo) and 298 supplemental/confirmatory (HIV-1/2 Geenius and HIV-1 Western Blot) assays even under harsh 299 environmental conditions. The HemaSpot device (about $6.00 per unit in the US, or $2.53-$3.00 300 outside US global public health clients) is easier to handle, requires shorter drying times, and 301 provides more convenient processing in the laboratory with decreased opportunity for potential 302 for cross-contamination than the standard 903 card ($2.30 per unit were spiked into whole blood, spotted on HS or 903 DBS, and stored at room 476 temperature/ambient humidity (<40%), or at 37°C or 45°C at 95% humidity for up to 180 days. 
